Xenon Pharmaceuticals Inc
XENEHealthcare|Biotechnology|Canada
$68.94
-2.05 (-2.89%)
Tangible Book
$13.85
About
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Stock Price
+109.1%(1Y)
Pipeline Summary
23 total trials8
Phase 1
7
Phase 2
11
Phase 3
0
Phase 4
Completed: 12Recruiting: 5Active: 1ENROLLING_BY_INVITATION: 3Terminated: 2
Active Trials (6)
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379Major Depressive Disorder
Phase 3Recruiting
Enrollment: 450 participants
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
NCT03796962Focal Epilepsy
Phase 2Active
Enrollment: 325 participants
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516Bipolar Disorder
Phase 3Recruiting
Enrollment: 400 participants
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142Primary Generalized Tonic-Clonic Seizures
Phase 3Recruiting
Enrollment: 160 participants
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100Focal Onset Seizures
Phase 3Recruiting
Enrollment: 360 participants
BioScore
5.1/10
Watchlist
Ownership
Recent Insider Trades
Cannon GillianSELL
2026-06-051,190 shares @ $53.14
PATOU GARYSELL
2026-06-051,322 shares @ $53.14
KENNEY CHRISTOPHER JOHNSELL
2026-03-131,410 shares @ $55.23
DiFabio AndreaSELL
2026-03-131,342 shares @ $55.23
MORTIMER IANSELL
2026-03-137,308 shares @ $55.23
Data last updated: Jul 12, 2026, 07:37 PM